RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-12-0605
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

TRAF6 Activation in Multiple Myeloma: A Potential Therapeutic Target

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2012English

CD26 Is a Potential Therapeutic Target by Humanized Monoclonal Antibody for the Treatment of Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

FOXM1 Is a Therapeutic Target in High-Risk Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Therapeutic Targeting of N-Cadherin Is an Effective Treatment for Multiple Myeloma

British Journal of Haematology
Hematology
2015English

EZH2 as a Therapeutic Target for Multiple Myeloma and Other Haematological Malignancies

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2018English

Is Mossy Fiber Sprouting a Potential Therapeutic Target for Epilepsy?

Frontiers in Neurology
Neurology
2018English

Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Kinase Inhibitor Screening Identifies CDK4 as a Potential Therapeutic Target for Melanoma

International Journal of Oncology
Cancer ResearchOncology
2015English

TAK1 Is a Pivotal Therapeutic Target for Tumor Progression and Bone Destruction in Myeloma

Haematologica
Hematology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy